# Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes

Study · id `cardio:ct-nct03230786` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03230786](<https://clinicaltrials.gov/study/NCT03230786>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03230786

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 255 participants.

## Technical summary

Registry record NCT03230786. Randomized; triple masking; primary purpose treatment. Start 2017-08-23 (actual); primary completion 2018-07-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 255 participants (enrolled count; ClinicalTrials.gov record NCT03230786, source copy `cardio:ctgov-nct03230786-2018-09-11`, retrieved 2026-10-26)
- Started: 2017-08-23 (actual) (ClinicalTrials.gov record NCT03230786, source copy `cardio:ctgov-nct03230786-2018-09-11`, retrieved 2026-10-26)
- Primary completion: 2018-07-09 (actual) (ClinicalTrials.gov record NCT03230786, source copy `cardio:ctgov-nct03230786-2018-09-11`, retrieved 2026-10-26)
- Completion: 2018-07-31 (actual) (ClinicalTrials.gov record NCT03230786, source copy `cardio:ctgov-nct03230786-2018-09-11`, retrieved 2026-10-26)
- Countries: Czechia; Denmark; Moldova; Poland; Romania; United Kingdom (ClinicalTrials.gov record NCT03230786, source copy `cardio:ctgov-nct03230786-2018-09-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03230786-2018-09-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Daily injection of KBP/placebo for 12 weeks as add-on to metformin
- Lead sponsor: KeyBioscience AG
- Lead sponsor class: INDUSTRY
- Collaborator: Nordic Bioscience A/S
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 473e2af512d76e4eb80e0b85e64d2bd653a0507cc7d2d2a2e25df395240d9f91
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
